Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
about
Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption.A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophreniaLeveraging the cortical cholinergic system to enhance attentionA reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.α7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimumnAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Effects of a ketogenic diet on auditory gating in DBA/2 mice: A proof-of-concept studyMaximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning.Mouse models for studying genetic influences on factors determining smoking cessation success in humans.Nicotine, Auditory Sensory Memory, and sustained Attention in a Human Ketamine Model of Schizophrenia: Moderating Influence of a Hallucinatory Trait.Unusual effects of nicotine as a psychostimulant on ambulatory activity in miceNicotine ameliorates NMDA receptor antagonist-induced deficits in contextual fear conditioning through high-affinity nicotinic acetylcholine receptors in the hippocampus.Physiological concentrations of choline activate native alpha7-containing nicotinic acetylcholine receptors in the presence of PNU-120596 [1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)-urea].Activation of functional α7-containing nAChRs in hippocampal CA1 pyramidal neurons by physiological levels of choline in the presence of PNU-120596In search of allosteric modulators of a7-nAChR by solvent density guided virtual screening.α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease.Role of the central cholinergic system in the therapeutics of schizophrenia.Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonistsPro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.A type-II positive allosteric modulator of α7 nAChRs reduces brain injury and improves neurological function after focal cerebral ischemia in rats.Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.Brain in flames - animal models of psychosis: utility and limitationsPhase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of SchizophreniaOccupancy of α7 Nicotinic Acetylcholine Receptors in the Brain by Tropisetron: A Positron Emission Tomography Study Using [(11)C]CHIBA-1001 in Healthy Human SubjectsA randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.A positive allosteric modulator of α7 nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischaemia.Effects of an alpha7 nicotinic receptor agonist and stress on spatial memory in an animal model of Alzheimer's disease.Rats and humans paying attention: cross-species task development for translational researchTargeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarkerα7-Containing nicotinic acetylcholine receptors on interneurons of the basolateral amygdala and their role in the regulation of the network excitabilityDifferential contribution of genetic variation in multiple brain nicotinic cholinergic receptors to nicotine dependence: recent progress and emerging open questions.Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatmentsNeurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1.3-(2,4-dimethoxybenzylidene)-anabaseine: a promising candidate drug for Alzheimer's disease?New drug developments in psychosis: Challenges, opportunities and strategies.Screening of Cognitive Impairment in Schizophrenia: Reliability, Sensitivity, and Specificity of the Repeatable Battery for the Assessment of Neuropsychological Status in a Spanish Sample.New Targets for Schizophrenia Treatment beyond the Dopamine HypothesisThe antiepileptic drug levetiracetam improves auditory gating in DBA/2 mice.
P2860
Q21129280-9CC41DD0-75D1-4BBA-A1E5-2BE265E90664Q21203917-3D628A89-0AD9-4F91-931F-8C07D9AAE605Q24598925-1F615745-2740-400E-9C3D-B37F7F1A2B7FQ24650678-3723F9B6-0BD0-4883-B272-43BCDBAACEBAQ26852967-B151C7C4-4C31-4031-8E48-63D33FC6C985Q30362464-704A25DA-6F49-49D8-B19A-CBD77CC3CCC3Q30368931-708732BC-F6F1-4242-9215-3275008C13D3Q30381001-6BE1D518-BD47-46F0-B602-D8381EC86B00Q30407039-B50AB0EA-68F7-4E50-AB0C-EA525256C138Q30422037-A5630485-510B-407A-9D28-E92A666B3D60Q30432964-9E2B38A8-043C-43E2-8220-AF742B2491B9Q30462575-8A422818-2B2D-47BE-A545-2EC430281F0BQ30468347-6848EA96-2405-46D4-B37C-53E8A79EFE51Q30470074-E7F786EA-499B-428D-9496-4B9B3DD8D46EQ33613585-9A5BF8E4-91C0-4B28-9793-3EAD2C8F4346Q33754362-3490B505-8BDF-43E1-9541-E43973A81D3FQ33811917-6FF82F9C-2EAF-42DE-AE4F-9620B507B1BDQ34501147-A0B0285E-8103-4656-8576-1D83ABC76762Q34608625-2285E5CB-69F0-43F1-A10D-9ACCCABD8F5DQ34868114-EA51E51A-F504-4FE2-B8A3-6D2D6405E273Q34926526-B7769DF2-6FCE-42EA-ADF0-2DEFE962F650Q34952107-F57807B6-EB5F-49B0-9F77-A79EB35CA661Q35048154-59DFF1C5-AE51-46E2-A9C0-4F4165CA88EAQ35683865-95358BB1-385A-461D-990F-396E22657213Q36579938-6414F626-CE3B-4893-8523-F9FB6921C9BBQ36600684-0EA29D37-896D-4D23-9A69-03E1345E8B34Q36775219-C7AB587E-FD30-4257-86EC-71154A61E495Q37122710-7F896BF6-847A-45B3-B3B6-127EC0107F4CQ37154745-1C69C53F-2689-444F-B184-E6A9D4572241Q37249653-A117CB1B-DC53-4E2B-97A7-C461F260E429Q37258840-9061A12D-3CDA-4959-A0BF-76A18E45BFE8Q37346227-1FAF8AF8-64ED-4247-BF7A-3F1489DCFA97Q37535489-931E83C4-88A9-412F-9496-70AF4AF7B38BQ37576675-2940A685-A1C1-4AFD-A979-6384029DB0F3Q37588242-062A35ED-B9C0-468B-9AE5-E891D42E37B3Q37980865-C7B8AFAA-7BB0-4A69-8D53-B5A84EB74EDAQ38926246-BC2AF338-8F20-49C1-8CED-A6197B3FB5F6Q40986257-9328C481-6AC2-40D7-971F-DC3322FC966BQ41573540-9E5985E2-FD04-4CF1-9DBC-71B5A19377FEQ41892321-6FD75802-25A1-458C-8A6A-1D97884D279C
P2860
Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
@ast
Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
@en
type
label
Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
@ast
Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
@en
prefLabel
Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
@ast
Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
@en
P2860
P1476
Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
@en
P2093
Karen E Stevens
P2860
P304
P356
10.1016/J.BCP.2007.07.015
P407
P50
P577
2007-07-17T00:00:00Z